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Besifloxacin hydrochloride (BSF) is a new ophthalmic antibiotic. However, its low water solubility 
limits its therapeutic efficacy. This article reported a novel lipid based drug delivery system to enhance 
ocular bioavailability of BSF. Cationic nanostructured lipid carriers (CNLC) were prepared and 
optimized by Box-Behnken design of using Design Expert Software®. Effect of concentration of three 
independent variables, Stabilizer, Solid lipid and Liquid Lipid were studied on three dependent variables 
Particle size, Polydispersity Index (PDI) and zeta potential of the CNLC particles. The surfactant, 
hexadecyltrimethylammonium bromide (CTAB) was used to optimize the surface charge of the 
nano-particles. The BSF loaded nano-particles, CNLC-BSF, were characterized fully. Rhodamine was 
trapped to CNLC-BSF for imaging. The cytotoxicity and cellular infiltration of CNLC-BSF were 
assessed by 2-dimensional (2D) and 3-dimensional (3D) conjunctival tissue model. It was revealed that 
the CNLC’s values, particle size, PDI and zeta potential remained stable over 2-week storage. The 
entrapment efficiency was around 80% for optimum formulation. The cell internalization of CNLC 
increased when CTAB concentration increased in CNLC-BSF. The formulation showed good 
penetration property through 3D tissue model. The cytotoxicity assessed by MTT assay showed 
minimum 60% cell viability on conjunctival fibroblast model for the optimized formula with inclusion 
of 0.6 mg/mL BSF.  
 





The world is heading towards a post-antimicrobial er  in which antibiotics would become inefficient to 
kill microbes because of ‘antimicrobial resistance’. In May 2015 World Health Assembly adopted a 
global action plan to combat ‘antimicrobial resistance’ [1]. One of the important objectives of the 
assembly was ‘to optimize the use of antimicrobial medicines in human and animal health’. Bacterial 
conjunctivitis is an ophthalmic condition arises because of aerobic microbes such as Staphylococcus 
aureus, which needs an antibiotic treatment regimen to reduc  the complications and associated chronic 
conditions. Ocular drug delivery is governed by eye anatomy such as low volume of cul-de-sac and 
physiology that decrease bioavailability of instilled drugs. The reflex processes like lacrimation and 
blinking reduce the drug residence time [2].   
 
The activity of Besifloxacin HCl (BSF) is broad spectrum antibiotic which inhibits bacterial enzymes, 
DNA gyrase and topoisomerase IV. BSF is active against drug-resistant strains such as ciprofloxacin 
resistant Staphylococcus aureus [3]. BSF is practically insoluble in water with log P value of 0.7 [4] 
Besifloxacin suspension 0.6% w/v for ophthalmic use(B sivance by Bausch & Lomb) is FDA in USA 
approved formulation for treatment of bacterial conjunctivitis [5]. BSF is the first and only 
fluoroquinolone exclusive for ophthalmic use [3]. The eye drops formulation is the most commonly 
prescribed dosage form, but it is shown rapid precorneal drainage hence it requires frequent instillation 
or high drug concentration in order to maintain required level of drug concentration in ocular fluid. To
resolve the problem of maintaining drug concentration n ocular fluid there is a need of the drug 
delivery system which provides a good retention andsustained ophthalmic delivery of the drug. So, 
these problems may be overcome by developing the formulation with good bioadhesion and drug 
retention property [6]. 
 
Number of applications of nanotechnology have been explored to address the challenge for prolonged, 
targeting and convenient delivery of ocular drugs in h gh quantity [7,8]. Among them, Solid Lipid 
Nanoparticles (SLNs) is an attractive technique [9-11]. Using lipid as colloidal carriers developed in the 
last decade bears advantage over the existing traditional carriers, such as emulsions, liposomes and 
polymeric nanoparticles. The advantages of SLN of small size, large surface area, high drug loading and 
the interaction of phases at the interfaces has attracted intensive study of SLN in past years. Cationic 
nanostructured lipid carrier (CNLC) is a modification of SLNs, which contain liquid lipid and possess 
positive charge on its surface hence they could adhere to negatively charged surface of conjunctival 
cells [12-13]. The bioadhesion of nanoparticles could increase ophthalmic retention and minimize 
precorneal drainage after instillation in the eye. H nce, bioavailability of the drug can be enhanced by 
formulating CNLC for ophthalmic instillation. 
 
The aim of the current study is to develop antimicrobial loaded cationic nanostructured lipid carrier to 
enhance ocular bioavailability using BSF as a broad-spectrum antibiotic. The current study describes th  
statistical technique to optimize BSF loaded CNLC formulation (CNLC-BSF) using Box-Behnken 
design as a strategy of Quality by Design better known as QbD. Three targeted parameters of the 
fabricated nanoparticles, particle size, poly disper ity index (PDI) and zeta potential have been select d 
to develop optimum formulation through quantity and types of solid lipid, liquid lipid and stabilizer. 
Gelucire 50/13 along with Hexadecyltrimethylammonium bromide CTAB were used to develop CNLC 
employing simple melt emulsification method. The optimized formulations were assessed for 
cytotoxicity and cellular intake capacity, and penetration of the formulation in 2D and 3D conjunctival 
fibroblast tissue models have been undertaken. The developed tissue models simulate biological 
condition hence the optimized formulation bears potential of ophthalmic drug delivery system. The 
nanotechnology-based drug delivery systems developed in this project may be employed after further 
investigation for treatment of chronic ocular diseas s such as conjunctivitis in which frequent drug 
administration is necessary [14-16].  
 
2. Materials and Methods 
2.1. Materials (lipid, stabilizer, surfactant) 
Besifloxacin Hydrochloride was purchased from Xi'an Shunyi Bio-Chemical Technology Co. Ltd China, 
Gelucire® 50/13, Compritol® 888 ATO and Labrafac PG® were kind gift samples from Gatteffose UK. 
Hexadecyltrimethylammonium bromide (CTAB), Rhodamine B octadecyl ester perchlorate and Hoechst 
stain solution were purchased from Sigma Aldrich. Remaining all chemicals were of analytical grade. 
 
2.2 Statistical experimental design 
Design-Expert software (Design-Expert 11.1.2.0, State-Ease Inc., Minneapolis, USA) was used to 
perform statistical calculation and experimental design. Box–Behnken design [8,17,18] was used with 
3-factors, 3-levels, and 17 runs for the optimization study. Independent variables were the concentration 
of Stabilizer (X1), Solid Lipid (X2), Liquid Lipid (X3) while dependent variables were Particle Size (Y1), 
Poly Dispersity Index (PDI) (Y2) and Zeta Potential (Y3) for optimization of besifloxacin hydrochloride 
loaded CNLC. 
Gelucire 50/13, Compritol 888 ATO and Labrafac PG were selected as the stabilizer, solid lipid and 
liquid lipid, respectively according to previous exp riments. Their concentrations were set at low, 
medium and high levels based on the results of initial trials. 3-Levels for independent variables were 
used as listed in Table 1. Objective formulation for the present study was selected for maximizing Zeta 
Potential while minimizing particle size and PDI. Analysis of variance (ANOVA) was employed for 
establishing the statistical validation of the polynomial equations generated by Design Expert software. 
The quadratic model was used for statistical processing as suggested by software. Feasibilities were 
conducted over the experimental design space to find the compositions of the optimized CNLC 
formulation. 3-Dimentional response surface plots were generated by the Design Expert software. 
 
2.3. Method of preparation of Besifloxacin loaded CNLC  
A simple melt emulsification and homogenization method was employed to make drug loaded CNLC 
[19-21]. Solid lipid (Compritol 888 ATO), Stabilizer (Gelucire 50/13) and Liquid Lipid (Labrafac PG) 
were transferred to a glass vial which was heated to 85°C. Then drug (besifloxacin) fluorescent dye 
(Rhodamine B) and CTAB was added to this vial. Distilled water, 9.4 ml was added to the vial and 
immediately vortexed (approx. 1200 rpm) until it formed the pre-emulsion. The pre-emulsion was 
transferred to a narrow glass beaker (50 mL) and maintained at 85°C using hot water bath. The 
pre-emulsion was sonicated using a probe sonicator at 25W, amplitude 70 for 8 min (Fisherbrand 
Model). The resulting nanoemulsion was cooled to rom temperature for solidification. The resultant 
nanodispersion was passed through cell strainer (40 µm) to remove any gritty particles. The resulted 
CNLC-BSF was stored in room temperature for further characterization. 
 
2.3.1 Preparation of BSF loaded CNLC with varying amount of CTAB 
BSF loaded CNLC formulation was prepared as mentioned i  previous section with varying amount of 
CTAB. Various formulation with concentration of 0, .05, 0.1, 0.2, 0.4, 0.8 mg/mL of colloidal 
dispersions were prepared to find its effect on zeta potential.  
 
2.4 Characterization of CNLC-BSF formulation 
2.4.1 Dynamic light scattering (DLS) 
2.4.1.1 Particle size and PDI 
Dynamic light scattering (DLS) method was used for measurement of particle size of CNLC [22]. 
Malvern instrument Nano ZS (Malvern, UK), Zetasizer 12 mm square polystyrene disposable cuvettes 
(DTS0012) were employed for measurement of particle siz  which was analysed by Zetasizer software 
by averaging 10 measurements. The sample was 500 times diluted before using for particle size 
measurement. Sample was equilibrated for 120 seconds a  measurement was done at 25°C. 
 
2.4.1.2 Zeta potential 
Malvern instrument Nano ZS (Malvern, UK), Folded Capill ry Zeta Cell (DTS1070) were employed for 
measurement of Zeta potential of CNLC through the Zetasizer software [23]. Sample was 500 times 
diluted then equilibrated for 120 seconds and measur ment was done at 25°C by averaging 30 
measurements.  
 
2.4.2 TEM  
Transmission Electron Microscopy was used to analyze the nanoparticle morphology (JEM-1230 JEOL, 
Japan). Dispersed sample was diluted with distilled water to make 0.05% w/v of solids dispersed 
throughout aqueous medium. 2 µL of diluted sample was spread over 300 mesh copper grid and allowed 
to dry for 1 hour before imaging [24]. 
 
2.4.3 Entrapment Efficiency 
Entrapment efficiency of drug was determined using ultracentrifuge filtration [9] indirect method. 
Besifloxacin loaded nanoparticulate suspension was filled in inner unit of ultra-filter fitted centrifuge 
tubes (MWCO 10K Amicon ultra-4, Merck Millipore Ltd. IRL) and filtrate was obtained in outer unit of 
ultrafiltration after centrifugation at 3000 G (Centrifuge Model) for 30 min. Presence of drug 
(Besifloxacin) in filtrate was determined using plate reader through UV absorbance method at 247 nm 
wavelength [25]. Percentage of Entrapment Efficiency (%EE) of drug (Besifloxacin) in CNLC was 
calculated using following formula [26]. 
 
%EE = (Initial amount of drug-Amount of free drug present in filtrate) / (Initial amount of drug) ×100 
 
2.4.5 FT-IR  
FTIR spectra of the particles were collected using a FT-IR spectrometer (Nicolet iS50, Thermo-Fisher, 
UK) [27,28]. Air dried sample of CNLC formulation or powder drug (besifloxacin) was suspended in 
acetone. The suspension was spread over a calcium fluoride window and dried at room temperatue. 
After the acetone evaporated, a thin layer of the samples was formed for the measurement. FTIR spectra 
were corrected on the baseline; also normalized and smoothed using OMNIC software. 
 
2.5 Cellular study of CNLC 
2.5.1 Cell source and conjunctival tissue model 
Conjunctival fibroblasts isolated from pig Tenon’s capsule + conjunctival tissue were used for all 
cellular assessment of the NCL particles. The extraction of the cells and formation of 3D Tenon’s 
capsule + conjunctival tissue model followed the protocols established in the lab [29,30]. In brief, 
porcine eyes were obtained from a local abattoir within a few hours of slaughter. The Tenon’s capsule 
tissue and bulbar conjunctival membrane were dissected out and then digested enzymatically using 3 
mg/ml dispase (Sigma-Aldrich, UK) followed by 3 mg/l collagenase (Sigma-Aldrich, UK). The 
obtained cells were cultured in high glucose Dulbecco’s Modified Eagles Medium (DMEM) 
supplemented with 10% foetal bovine serum, 1% L-glutamine and 1% antibiotics (penicillin & 
streptomycin) at 37°C, 5% CO₂. The 3D conjunctival tissue model was constructed by incorporating the 
fibroblasts into 3 mg/ml collagen hydrogels (Fisher Scientific, UK) at a density of 4 x 104 cells per 50 µl 
gel. After the hydrogels were set, the supplemented culture medium was added for culture. 
 
2.5.2 Cytotoxicity study (MTT assay)  
MTT assay was performed for cytotoxicity study of Besifloxacin loaded CNLC. Fibroblast cells were 
seeded in a 96-well plate with the density of 4000 viable cell per well. After the cells were fully att ched 
and stretched, the medium was replaced with 1%, 5% and 10% of besifloxacin suspension (0.6 mg/mL) 
and two optimum CNLC-BSF formulations containing 0.6 mg/mL of besifloxacin with low (0.2 mg/mL) 
and high (2.5 mg/mL) concentration levels of CTAB in triplicate [13,27]. After 1 hour of incubation at 
37°C, old medium from each well were replaced with the fresh medium containing 5% MTT solution (5 
mg/mL in Phosphate buffered saline) and incubated for 2 hours until formazan crystals appeared. The 
medium was removed from each well and 120 µL dimethyl sulfoxide (DMSO) was added to solubilize 
the formazan crystals. Absorbance DMSO solution wasmeasured at 247 nm by UV detector using 
microplate reader (BioTek Synergy II). Untreated cells were taken as control and assumed 100% 
viability and cells without addition of MTT were used as blank for the calibration of spectrophotometer 
to zero absorbance. Percentage viability was calculated using the following formula [26]:  
 
%Cell viability = (Absorbance of each well) / (Average absorbance of untreated wells) ×100 
 
2.5.3 CTAB concentration in the formula and cell internalization in 2D cell model 
To assess the effect of CTAB concentration in the optimum CNLC formulation on cell internalization 
capacity, five CNLC formulation with variable concentration of CTAB (0 mg/mL, 0.1 mg/mL, 0.2 
mg/mL, 0.4 mg/mL and 0.8 mg/mL) were used to culture fibroblast cells using above setting. After 1 
hour incubation of the CNLC formulations, fresh culture medium was replaced and cell images were 
observed and collected using a confocal microscope (Olympus, UK) [29,31].  
 
2.5.4 Cell intake and penetration of NLC in 3D tissue model  
After the fibroblast cells in collagen gel became elongated and distributed evenly, the culture medium 
was replaced with fresh culture medium containing 1%, 5% and 10% of optimum CNLC formulation 
which was prepared to contain 0.2 mg/mL of CTAB, besifloxacin and Rhodamine B (fluorescent dye). 
After 1 hour incubation, the CNLC formulation contai ing media were replaced with normal culture 
medium. The cell morphology and NLC locations were observed and the images were collected using a 
confocal microscope [29,31].  
2.5.5 Quantification of NLC intake 
105 conjunctiva fibroblast cells were seeded in T-25 flasks and incubated for 48 hours at 5% CO2 at 
37°C. After that culture media was replaced with fresh culture media containing 5% optimum CNLC 
formulation containing 0.6 mg/mL of besifloxacin. The flask was incubated for 1 hour then culture 
medium was removed and washed thrice with PBS. Then cells were passaged, and the cell-pellet was 
collected. Then 250 µL DMSO was added to cell-pallet to dissolve all cell content along with 
internalized besifloxacin. The solution was centrifuged at 1200 rpm for 3 min and supernatant DMSO 
was transferred to 96-well plate to read the absorption at 247 nm in a microplate reader (BioTek 
Synergy II). Pure DMSO was taken as blank [26]. Concentration of besifloxacin present in DMSO was 
determined using a besifloxacin calibration curve pr pared using known concentration solution of 
besifloxacin in DMSO. The achieved concentration of BSF in fibroblast cells was more than required 
minimum inhibitory concentration (MIC90) of BSF i.e. 2 μg/mL [3]. 
 
3. Results and discussion 
3.1 Optimization of NLC-BSF formulation 
The critical independent variables for optimization were identified through literature survey and trial 
method. The influential parameters were identified to be solid lipid concentration, stabilizer 
concentration and liquid lipid concentration. The Box Behnken design method (BBD) was used for 
optimization as it requires fewer runs than other statistical methods. Also, BBD is more efficient in 
optimization as compare to one or two variable study at a time because BBD is useful to analyze 
combine effect of different variables on response. The BBD suggested 17 formulations having different 
combination of concentration of independent variables. The values of three dependent variables, particle 
size of NLC, PDI and zeta potential were found in the range of 98.04 to 230.12 nm, 0.144 to 0.351 and 
12.83 to 26.65 respectively (Table 2). The 3-Dimentional response graphs as shown in Figure 1 were 
obtained for Y1, Y2 and Y3 respectively, representing the interaction effects of the factors (X1, X2 and X3) 
on the responses (Y1, Y2 and Y3). Mathematical expressions for various responses in terms of 
independent variables were obtained as quadratic equations [8]. Optimum formula for CNLC is as 
shown in Table 3 and the desirability index of formulation was found to be 0.278 through Design Expert 
Software. 
 
3.1.1 Effect of independent variables on Particle size 
Particle size of NLC formulation need to be lower than 1000 nm for ophthalmic use. Lower particle size
favorites stability as the particles remain in Brownian motion which prevent sedimentation [12]. Effect 
of stabilizer (Gelucire 50/13) on particle size was found to be more prominent where increase in 
stabilizer concentration led to reduction in particle size (Fig. 1A-A’’). This effect may be attributed to 
PEG present inside gelucire 50/13 which acted as surfactant hence it should be responsible for reduction 
in interfacial tension [32].  
Particle size (Y1) 
Y1 = 238.432 - 14.4091 X1 -0.52225 X2 + 5.56062 X3 - 0.073875 X1 X2 - 0.103475 X1 X3 + 0.01125 X2 
X3 + 0.32192 X1
2 + 0.083056 X2
2 - 0.035325 X3
2 
 
3.1.2 Effect of independent variables on PDI 
Polydispersity Index (PDI) is a measure of particle size homogeneity which varies from 0 to 1. If the 
value of PDI is closer to zero, then it indicates higher uniformity or homogeneity and maximum 
particles are of nearly same size and size distribution is narrow [33]. The combined effect of stabilizer 
and solid lipid concentration on PDI was studied using Box Behnken model. It was found that minimum 
concentration of both variables i.e. stabilizer andsolid lipid increased the PDI value. The effect may be 
attributed to reduction in concentration of total solid substance in formulation and proportional increase 
in liquid lipid concentration which ultimately reduced the consistency of internal phase (Fig. 1B-B’’). 
Low consistency of internal phase needed comparatively more time for solidification hence it provided 
enough time for internal phase to orient itself in regular spherical shape under influence of interfacial 
tension [8]. Also, size reduction become more regular with low consistency of internal phase hence PDI
reduces with proportional increase in concentration of liquid lipid (when compared to solid lipid) in 
formulation. 
PDI (Y2) 
Y2= - 0.260158 + 0.0255812 X1 + 0.01505 X2 + 0.0061875 X3 - 0.00079 X1 X2 - 0.0004975 X1 X3 + 
0.000005 X2 X3 
 
3.1.3 Effect of independent variables on Zeta Potential  
Also, it was found that increase in stabilizer concentration caused reduction in zeta potential. This may 
be because of covering/shielding of CTAB by the stabilizer (Fig. 1C-C’’). The effect of different CTAB 
concentration in optimum formulation was then separately studied and it was found that increase in 
CTAB concentration from 0 mg/mL to 0.8 mg/mL resulted in increase in zeta potential of CNLC from 
-7.9 mV to +23.9 mV hence the 0.2 mg/mL CTAB concentration was selected as it provides good zeta 
potential of +16.6 mV. 
Zeta potential (Y3) 
Y3 = 22.0875 - 1.12325 X1 + 1.1955 X2 - 0.9785 X3 - 0.01475 X1 X2- 0.0135 X1X3 - 0.054 X2 X3 + 
0.0318 X1
2 + 0.00255 X2
2 + 0.0862 X3
2 
3.2 Validation of statistical experimental design 
The actual experimental values of the responses verus corresponding predicted values plot was 
generated by Design Expert software for particle siz , PDI and zeta potential to obtain scatter plot as 
shown in Fig. 2a-c whereas Fig. 2a’-c’ indicate corresponding run sequence residual plot. The R2 value 
for particle size, PDI and zeta potential was found to be 0.9991, 0.9911 and 0.967 respectively. The 
software generated best fit model for all the three variables was quadratic model with R2 value or 
coefficient of correlation nearly equal to unity, the lack of fit F-value for all the three responses were 
non-significant for quadratic model which indicate good fit, as shown in Table 4. Also, the difference 
between predicted R2 and adjusted R2 was found to be less than 0.2 for all the three responses i.e. Y1, Y2 
and Y3 which indicate both the values of R
2 for all responses were in reasonable agreement with each 
other.  
 
The run sequence residual plot is a scatter plot in which each residual is plotted versus an index i.e. 
order of making formulation with respect to time. Figure 2a’-c’ shows that the residuals from a 
straight-line fit to the particle size, PDI and zeta potential data plotted in run order. This plot represents 
good randomized run order. For all these reasons the model can be used to navigate the design space for 
all the three responses (particle size, PDI and zeta po ential) also it is valid for the purpose. 
3.3 Characterization of optimum CNLC-BSF formulation 
3.3.1 Dynamic light scattering (DLS) 
3.3.1.1 Particle size and PDI 
DLS technique measures the Brownian motion of suspended particle in liquid medium and correlates it with 
particle size [6]. Brownian motion of particles is inversely proportional to particle size. The knowledg  of 
viscosity and temperature plays important role in determination of particle size. The measurement was 
conducted at 25°C when dispersion medium was water. DLS technique measure the translational diffusion 
coefficient of the particles within the liquid and the particle size of the particle could be determined using 
Stokes-Einstein’s equation in term of z-average diameter, which is average hydrodynamic diameter of the 
nanoparticles [33]. Higher concentration of solid lipid found to increase particle size of CNLC. Z-average 
particle size (hydrodynamic diameter) was found to be 173.6 nm with PDI 0.188. 
 
3.3.1.1 Zeta potential 
Zeta potential is the potential difference between shear plane and electroneutral region of dispersion medium 
[34]. Zeta potential measurement has been done by dtermining particle velocity due to electrophoresis under 
influence of electric field [6]. The zeta potential was in the range of +12.83 mV to +26.65 mV when a 
constant concentration of CTAB (0.2 mg/mL) was used while varying the concentration of independent 
variables (stabilizer, solid lipid and liquid lipid) uring optimization of CNLC. The change in zeta potential 
in CNLC for constant CTAB concentration was attributed to shielding effect of Gelucire 50/13.  
 
3.3.1.2 Effect of CTAB on zeta potential 
CTAB induces positive surface charge on CNLCs. This led to increase in positive zeta potential as shown in 
Figure 3. When the formulation parameters (stabilizer, solid lipid and liquid lipid) for optimum formulation 
were kept constant and variable concentration of CTAB from 0 mg/mL to 0.8 mg/mL were used it resulted in 
increase of zeta potential from -7.9 mV to +23.9 mV. The zeta potential for optimum CNLC-BSF with CTAB 
concentration of 0.2 mg/mL was found to be +16.6 mV, confirmed through nanozetasizer software. 
Formulation with a CTAB concentration 0.2 mg/mL showed good zeta potential i.e. more than +16.0 mV. 
 
3.3.2 TEM 
Pre-emulsion sample made for optimized CNLC formulation containing BSF and rhodamine B was 
immediately removed before sonication but after 3 minutes vortex mixing of lipid phase with aqueous 
phase in warm condition (85°C) and allowed to solidify. The TEM image before sonication (Fig. 4A) 
reveals larger particle size (> 1000 nm). After sonication TEM image (Fig. 4B) for corresponding 
CNLC formulation was found to be of small size (<300 nm) with more uniformity and regular spherical 
shape. The particle size was in accordance with dynamic light scattering analysis results. This study 
confirmed that proper size reduction and good PDI was achieved because of sonication. 
 
3.3.3 Entrapment efficiency 
Entrapment efficiency of CNLC-BSF formulation by ultracentrifuge filtration indirect method was 
found to be around 80%. This means maximum amount (80%) of BSF was entrapped in CNLC lipid 
core and 20% was available in aqueous phase for immediate release at the site of action which is the 
property of good sustained drug delivery system. The formulation was found to be stable for a period 
two weeks during storage and there was no significat hange in entrapment efficiency.  
 
3.3.4 FTIR 
FT-IR spectroscopy was performed to investigate any chemical interaction between the encapsulated 
drug (BSF) and CNLC excipients. Figure 4C shows FTIR spectra of plain CNLC formulation without 
drug (a), besifloxacin loaded CNLC formulation (b) and besifloxacin HCl powder (c). In all the three 
spectra it shows strong peak at 3100 cm-1 because of -OH stretching. Strong peak near 1670 cm-1 in all 
the three spectra represented C=O carbonyl stretching. There was no significant difference between 
spectra of plain CNLC formulation without drug (a), besifloxacin loaded CNLC formulation (b) hence 
BSF remained physically entrapped inside CNLC withou  chemically interacting with excipients. 
 
3.4 Cellular interaction of optimum formulation 
3.4.1 Cytotoxicity study 
Figure 5 reveals that cell viability for besifloxacin suspension through MTT assay was high and reached 
above 90% when besifloxacin suspension was diluted at 1% and 5% with culture media. For 1% and 5% 
optimum formulation (containing 0.2 mg/mL of CTAB) added to culture media the cell viability was 
found to be above 80% while for 1% of optimum formulation (containing 2.5 mg/mL of CTAB) added 
to culture media the cell viability was found to be above 60%. Results suggest that toxicity of optimum 
CNLC formulation was CTAB-concentration dependent. Cytotoxicity may have increased because of 
accumulation of excessive positive charge inside cell due to CTAB as evident from cell internalization 
study. 
 
3.4.2 CTAB concentration effect on internalization of CNLC in 2D fibroblast cell model 
CTAB concentration from 0 mg/mL to 0.8 mg/mL in besifloxacin loaded optimum CNLC formulation 
demonstrated strong effect on cell intake [35]. Figure 6 shows gradient increase in intensity of 
fluorescence when laser power of confocal microscope was maintained constant, which revealed that, 
there was increase in cellular intake of CNLC when CTAB concentration was increased. Cellular intake 
maximized with increased in CTAB concentration because of increase in zeta potential (from -7.9 mV to 
+23.9 mV) which allowed firm adherence to negatively charged cell membranes [12]. In separate 
experiment the rhodamine and BSF loaded optimum CNL formulation (containing 0.2 mg/mL CTAB) 
was selected to investigate cellular internalization using confocal laser microscopy.  
 
3.4.3 Internalization of CNLC formulation using 3D model 
Figure 7 shows z-stack images of rhodamine B and BSF loaded CNLC formulation (containing 0.2 
mg/mL CTAB) penetrating through 3D conjunctival tissue model. The CNLC formulation have capacity 
to penetrate collagen gel and fibroblast cells because of its fine size and bio-adhesion property. Even 1% 
of the formulation in culture medium can penetrate cells within one hour as evident from confocal laser 
microscopy imaging. Corresponding cell images suggest the CNLC formulation internalized after 
penetrating through thick collagen gel based conjunctival tissue model. The high bioadhesion of CNLC 
on conjunctiva facilitated the internalization of CNLC in upper conjunctival cells. We recognize that to 
allow CNLC for clinical application, more rigorous cytotoxicity test by ex vivo and in vivo models have 
to be undertaken, their effects on other tissue, e.g. sclera require further investigation.  
 
4. Conclusion  
Besifloxacin HCl loaded Cationic Nanostructured Lipid Carriers (CNLC) were developed for 
conjunctivitis as novel ocular drug delivery system. Design expert Software was employed for statistical 
optimization of formulation and Box-Behnken design was used for this purpose. Data analysis and 
processes validation suggested validity of design space because actual values of formulation parameters 
were very close to predicted values. Characterization of optimum CNLC formulation for various 
parameters like particle size, PDI, zeta potential, TEM, FT-IR, entrapment efficiency revealed that the
technique of formulation production was robust and bears potential of scale-up. Particle size was in 
range i.e. 98.04 to 230.12 nm which is suitable for ophthalmic use. Zeta potential was in range from -7.9
mV to +23.9 mV suggesting formulation parameters can be modulated to obtain desired zeta potential and
this is crucial for bio-adhesion with negatively charged cell membrane. In vitro study of optimum 
formulation for cytotoxicity and collagen gel penetration suggested that developed formulation was safe 
and effective for ophthalmic use. The achieved concentration of BSF in conjunctival fibroblast cell 
model was more than minimum inhibitory concentration (MIC90) of BSF i.e. 2 μg/mL. The simple melt 
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Figure 1 A-A’’) 3D-response surface plot showing effect of independent variables on particle size of 
NLC formulation; B-B’’) 3D-response surface plot showing effect of independent variables on 
polydispersity index (PDI) of NLC formulation; C-C’’) 3D-response surface plot showing effect 
of independent variables on zeta potential of NLC formulation. 
Figure 2 Scatter plot showing predicted values vs actual experimental values for a) Particle size, b) PDI 
and c) zeta potential; and run sequence residual scatter plot for a’) Particle size, b’) PDI and c’) 
zeta potential. 
Figure 3 Effect of CTAB concentration on zeta potential of CNLC. The values were expressed by mean 
± SD, n = 3.  
Figure 4 Characterization of CNLC particles. Representative TEM image of the produced particles in A) 
pre-emulsion before sonication, B) besifloxacin and rhodamine-B loaded optimum CNLC 
formulation; and FTIR graphs in C): (i) plain CNLC formulation without BSF; (ii) besifloxacin 
loaded CNLC formulation and (iii) besifloxacin HCl powder. 
Figure 5 MTT assay results. Graph indicating % cell viability when incubating with 1% besifloxacin 
suspension (0.6 mg/mL) or 1% NLC formulation with 0.2 mg/mL CTAB, or 1% NLC 
formulation with 2.5 mg/mL CTAB, (n=3). 
Figure 6 Confocal scanning laser microscopic images showing the effect of CTAB concentration in 
fabricating CNLC-BSF particles on the particle intaking in a 2D conjunctival model, 
manifesting as the increased rhodamine intensity in cells. 5% of the CNLC-BSF particles was 
added to culture media. a) 0 mg/mL (no CTAB); b) 0.1 mg/mL; c) 0.2 mg/mL; d) 0.4 mg/mL; e) 
0.8 mg/mL. Scale bar = 50 µm, (n=3).  
Figure 7 Confocal scanning laser microscopic image showing the permeation of CNLC-BSF particles 
in a 3D conjunctival tissue model. 1 % of CNLC-BSF particles containing 0.2 mg/mL of CTAB 
was added to culture media. a) the 2D image of particle intaking in the cells with Hoechst dye to 
stain nucleus (blue), scale bar = 50 µm; b) z-stack image, scale bar = 200 µm. The CNLC-BSF 
particles were rhodamine labeled (red). (n=3) 
 
Table caption 
Table 1 Independent variables (factors) of Box–Behnken design and constraints of dependent variables 
(responses) for optimization of besifloxacin loaded CNLC  
Table 2 Observed responses in Box–Behnken statistical design for development and optimization of 
besifloxacin loaded CNLC with predicted values generated by Design Expert Software. 
Table 3 Optimum formula for BSF-CNLC with 0.2 mg/mL CTAB 
Table 4 Statistical model fitting summary report extracted from Design Expert Software. 
 
 
Table 1: Independent variables (factors) of Box–Behnken design and constraints of dependent variables (responses) for optimization of 
besifloxacin loaded cationic NLC  
Factors Name Units Actual Levels used 
   Low (-1) Medium (0) High (+1) 
X1 Stabilizer mg/mL 10.00 20 30.00 
X2 Solid Lipid mg/mL 10.00 20 30.00 
X3 Liquid Lipid µL/mL 10.00 15 20.00 
Response   Optimization Goal 
Y1 Particle size nm Minimize 
Y2 Polydispersity Index 
(PDI) 
 Minimize 












Table 2: Observed responses in Box–Behnken statistical design for development and optimization of besifloxacin loaded cationic NLC with 































X1 X2 X3 Y1 Y2 Y3 Y1 Y2 Y3 
1 6 10 10 15 183.25 0.146 18.61 183.86 0.1456 19.45 
2 8 30 10 15 105.85 0.351 14.85 107.42 0.3509 15.32 
3 16 10 30 15 230.12 0.290 26.65 228.55 0.2901 26.18 
4 12 30 30 15 123.05 0.178 17.21 122.44 0.1784 16.37 
5 1 10 20 10 177.99 0.153 23.17 178.52 0.1465 22.80 
6 13 30 20 10 98.04 0.250 17.10 97.61 0.2432 17.10 
7 4 10 20 20 215.02 0.153 26.62 215.46 0.1598 26.62 
8 10 30 20 20 114.35 0.150 18.02 113.82 0.1565 18.39 
9 7 20 10 10 100.95 0.181 12.83 99.81 0.1879 12.36 
10 17 20 30 10 127.50 0.166 20.78 128.54 0.1724 21.62 
11 2 20 10 20 126.31 0.156 21.11 125.27 0.1496 20.27 
12 11 20 30 20 155.11 0.144 18.34 156.25 0.1371 18.81 
13 5 20 20 15 122.15 0.145 16.56 120.04 0.1534 15.85 
14 3 20 20 15 119.05 0.152 16.22 120.04 0.1534 15.85 
15 15 20 20 15 118.59 0.161 16.75 120.04 0.1534 15.85 
16 14 20 20 15 118.91 0.156 14.14 120.04 0.1534 15.85 




Table3. Optimum formula for BSF-CNLC with 0.2 mg/mL CTAB 
Ingredient Quantity 
Drug (BSF) 0.6 mg/mL 
Stabilizer 15.08 mg/mL 
Solid Lipid 19.85 mg/mL 
Liquid Lipid 17.46 µL/mL 
CTAB 0.2 mg/mL 
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